Regulus Therapeutics
RGLS
C$11.24
Share price
0.00%
Change (1 day)
343.30%
Change (1 year)
Categories
Operating Margin for Regulus Therapeutics (RGLS)
Operating Margin as of July 2025 (TTM): -118.00%
According to Regulus Therapeutics's latest financial reports and stock price the company's current Operating Margin is -118.00%. At the end of 2020 the company had an Operating Margin of -157.21%.
Operating Margin history for Regulus Therapeutics from 2012 to 2020
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2020 | -157.21% | -42.23% |
| 2019 | -272.12% | -99.6% |
| 2018 | -67,565.28% | -32.53% |
| 2017 | -100,141.67% | 1361.01% |
| 2016 | -6,854.27% | 2451.52% |
| 2015 | -268.64% | -63.65% |
| 2014 | -739.07% | 673.78% |
| 2013 | -95.51% | -30.36% |
| 2012 | -137.15% | 155.7% |
| 2011 | -53.64% | -70.41% |
| 2010 | -181.25% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 GlaxoSmithKline GSK | 13.32% | -111.29% | 🇬🇧 UK |
 Sanofi SNY | 15.12% | -112.81% | 🇫🇷 France |
 Biogen BIIB | 17.85% | -115.13% | 🇺🇸 USA |
 AstraZeneca AZN | 16.07% | -113.62% | 🇬🇧 UK |
 Alnylam Pharmaceuticals
ALNY | -16.78% | -85.78% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | -169.73% | 43.84% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.82% | -110.86% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | -61.01% | -48.30% | 🇺🇸 USA |
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.